166 related articles for article (PubMed ID: 22562250)
1. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.
Weiler M; Pfenning PN; Thiepold AL; Blaes J; Jestaedt L; Gronych J; Dittmann LM; Berger B; Jugold M; Kosch M; Combs SE; von Deimling A; Weller M; Bendszus M; Platten M; Wick W
Oncogene; 2013 Feb; 32(9):1099-109. PubMed ID: 22562250
[TBL] [Abstract][Full Text] [Related]
2. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
6. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA
Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981
[TBL] [Abstract][Full Text] [Related]
8. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
10. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
[TBL] [Abstract][Full Text] [Related]
11. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
12. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Fan Q; Aksoy O; Wong RA; Ilkhanizadeh S; Novotny CJ; Gustafson WC; Truong AY; Cayanan G; Simonds EF; Haas-Kogan D; Phillips JJ; Nicolaides T; Okaniwa M; Shokat KM; Weiss WA
Cancer Cell; 2017 Mar; 31(3):424-435. PubMed ID: 28292440
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
[TBL] [Abstract][Full Text] [Related]
18. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
19. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
20. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
